We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood-Based Multi-Cancer Test Sets New Standard for Ultra-Sensitive and Early MRD Detection

By LabMedica International staff writers
Posted on 04 Jun 2025

Detecting minimal residual disease (MRD) and early recurrence in cancer patients remains a major clinical challenge, particularly for those with early-stage breast cancer. More...

Despite curative-intent treatment, up to 25% of patients, especially those with estrogen receptor-positive (ER+) tumors, will eventually experience recurrence, often years later. Now, a first-of-its-kind, blood-based multi-cancer MRD platform that tracks structural variants (SVs) offers ultra-sensitive and specific detection of cancer recurrence.

Pathlight from SAGA Diagnostics (Morrisville, NC, USA) operates by leveraging structural variants, tumor- and patient-specific genomic features such as breakpoints and rearrangements, as highly informative biomarkers. These SVs are identified through whole-genome sequencing and proprietary informatics designed to detect stable SV breakpoints, creating a personalized genomic fingerprint for each patient’s tumor. These fingerprints are then orthogonally validated and tracked using SAGA’s proprietary multiplex digital PCR system, which allows precise, rapid, and quantitative MRD detection from a simple blood draw. The method offers unprecedented sensitivity, breaking the 1 part per million (ppm) barrier, to detect MRD as early as possible. The clinical validity of Pathlight was established in the TRACER study (cTdna evaluation in eaRly breAst canCER), published in Clinical Cancer Research. The retrospective analysis included 100 patients with stage I–III breast cancer of all subtypes undergoing standard neoadjuvant and adjuvant therapy.

Pathlight demonstrated 100% sensitivity and 100% specificity, with a 13.7-month lead time to recurrence confirmed by imaging or clinical symptoms. The test also achieved a baseline detection rate of 96% overall and 94% in ER+ breast cancer, suggesting significant advantages over first-generation circulating tumor DNA (ctDNA) assays. SAGA Diagnostics has announced the U.S. commercial launch of its Pathlight test for the detection of residual disease and recurrence. With analytical validation across multiple cancer types, Pathlight is already in use in clinical studies by top pharmaceutical companies and major cancer centers. Its personalized, off-the-shelf design makes it a powerful surveillance tool for long-term monitoring and individualized intervention, with potential use across both solid tumors and hematologic malignancies.

“By tracking structural variants — stable, unique, and tumor-defining fingerprints of each patient’s cancer — Pathlight enables interception of recurrence at its most treatable and potentially curable stage,” commented Roopom Banerjee, Executive Chairman of SAGA Diagnostics. “Our goal is to deliver the most accurate, trusted results that provide assurance and support confident, informed treatment decisions. Our published, peer reviewed data demonstrates the clinical validity of Pathlight in breast cancer and its potential power across all solid tumors and heme malignancies. SAGA has further partnered with leading clinicians, institutions, and biopharma to bring Pathlight to market and best serve patients.”

Related Links:
SAGA Diagnostics


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.